Activated charcoal to treat acute poisoning
Official title: CHARPP (Activated CHARcoal in Poisoned Patient): RCT Pilot Study
Run by Laval University · NCT05471479 · Data updated 2026-11-12
This pilot will test whether giving activated charcoal within 6 hours to adults and children who swallowed a substance that charcoal can bind helps prevent worsening toxicity and shortens hospital and ICU stays.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Laval University Academic / other |
| Locations | 1 site (Québec, Quebec) |
| Status | Recruiting |
| Started | July 16, 2025 |
| Main results expected | June 1, 2026 |
| Study ends | February 1, 2027 |
| Registry record updated | January 29, 2026 |
| Trial ID | NCT05471479 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults and children who present to the enrolling hospital within 6 hours after ingesting a substance known or suspected to be adsorbable by activated charcoal and who have no contraindication to charcoal.
✕Probably not a fit
Patients who ingested substances not adsorbed by activated charcoal, require other gastrointestinal decontamination methods, have contraindications to charcoal, or present more than 6 hours after ingestion are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, pilot feasibility trial comparing early single-dose activated charcoal versus standard supportive care in people (adults and children) who present within 6 hours after ingesting a carbo-adsorbable toxic substance. Participants are randomly assigned to receive activated charcoal or no charcoal and undergo standard clinical assessments and follow-up. The primary aim is to determine feasibility metrics (recruitment targets and protocol adherence) before launching a larger multicenter RCT, while also collecting preliminary clinical outcomes such as hospital and ICU length of stay and severity of poisoning. Safety and tolerability of activated charcoal will also be tracked.
Why it matters
Potential benefit: If successful, early use of activated charcoal could reduce poisoning severity, shorten hospital and ICU stays, and lower related healthcare costs and complications.
How similar studies have gone: Activated charcoal is widely used and supported by observational data and poison-center practice, but randomized controlled evidence in diverse adult and pediatric populations is limited, so this trial addresses an important evidence gap.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult and pediatric patients who presented to the hospital less than 6h after the ingestion of a potentially toxic dose of a carbo-adsorbable substance (substance adsorbed by activated charcoal ). * Patients who can receive the intervention within 6 hours of proven or suspected intoxication Exclusion Criteria: * Patients requiring or who will likely require another gastro-intestinal decontamination method; * Patients who have contraindication to the use of activated charcoal; * Patients who ingested a substance with an entero-hepatic circulation requiring multi-dose AC; * Patients who have no clinical equipoise for the use of activated charcoal as per the attending physician.
Where it's running
-
CHU de Québec - Université Laval
Québec, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Maude St-Onge, MD PhD FRCPC — CHU de Québec - Université Laval
- Study coordinator: Maude St-Onge, MD PhD FRCPC
- Email: maude.st-onge.med@ssss.gouv.qc.ca
- Phone: 418-932-5357
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bringing preventive cardiovascular care to Indigenous and remote communities
This project tests a mobile health unit to screen and provide culturally safe cardiovascular and metabolic care for Indigenous and remote communities in Canada.
-
Immersive virtual reality mindfulness for older adults in long-term care
This trial tests whether an immersive VR mindfulness program is feasible and safe for seniors with mild to moderate cognitive impairment living in long-term care, and whether it can improve well-being.
-
Home-based Pedal Exerise Therapy for Moderate-to-Severe PAD
This pilot study tests whether a 12-week home-based pedal exerciser program, guided remotely, can help adults with moderate-to-severe PAD improve walking and function.
-
Virtual reality relaxation for insomnia
Researchers are testing a VR relaxation program to see if it helps adults with insomnia sleep better and feel less tense before bed.
-
Right heart function after cardiac surgery: does respiratory acidosis matter?
This study looks at whether respiratory acidosis after heart surgery affects how well the right side of the heart works in ICU patients.
-
Moving Without Fear or Pain: Virtual Reality Rehabilitation for Older Adults with Chronic Pain
A virtual reality program is tested to see if it helps adults 65 and older who have chronic pain and fear of movement feel better and move more.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.